aviscera bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
IL-18 ELISA Kit, Protein & Antibody

Alternative name:

  • IFN-gamma inducing factor
BACKGROUND: Interleukin-18 (IL-18) plays an important role in mediating cytokine cascade leading to coronary artery lesions (CALs) in Kawasaki disease (KD). However, our research suggested that the literature regarding IL-18 and KD is limited. Consequently, this study aimed to evaluate the correlation between IL-18 and CALs in patients with KD. METHODS: In this prospective study of 14 children with KD (seven without and seven with CALs in the acute phase), we obtained patient measurements of a series of serum IL-18 levels in the acute, subacute, and convalescent phases. Serum IL-18 levels were measured with a Bio-Plex cytokine assay. Control samples were obtained from 18 febrile children with viral infection. RESULTS: Compared with febrile controls, patients with acute-stage CALs [postintravenous immunoglobulin (post-IVIG) period] had a significantly higher IL-18 level (88.4 ± 20.7 vs 56.0 ± 35.0 pg/mL, p = 0.006). However, those without acute-stage CALs (post-IVIG period) lacked similarly elevatedIL-18 level readings (62.0 ± 40.6 vs 56.0 ± 35.0 pg/mL, p = 0.762). The IL-18 level of patients with acute-stage CALs did not decrease significantly until the convalescent phase (97.4 ± 55.8 vs 38.7 ± 22.6 pg/mL, p = 0.018), but for those without CALs, it decreased significantly in the subacute phase (60.2 ± 37.4 vs 23.6 ± 13.8 pg/mL, p = 0.018). In the subacute stage, there was a significant difference of IL-18 level between patients with and without acute-stage CALs (p = 0.048).CONCLUSION: Our data show that IL-18 levels were elevated in the acute phase of KD and might be related to the formation of CALs.
Weng KP et al. J Chin Med Assoc. 2013 Jun 13. pii: S1726-4901(13)00105-6. doi: 10.1016/j.jcma.2013.04.005.

Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure

Although interleukin (IL)-18 is a member of the IL-1 family of ligands, IL-18 appears to have unique characteristics, particularly in the regulation of the T helper type 1 (Th1) response. Th1 responses are required for tumor surveillance, killing intracellular organisms, and to provide help for antibody production. In patients with chronic renal failure, the well-known immunosuppression contributes to a failure to respond to infectious challenges and vaccinations. The most salient biological property of IL-18, linking this cytokine to the Th1 response, is its ability to induce interferon gamma (IFN-gamma). In fact, IL-18 was originally identified as an IFN-gamma-inducing factor, and IFN-gamma production is the hallmark of the Th1 response. Dysregulation of IFN-gamma production resulting from reduced activity of IL-18 would explain one of the mechanisms of immunosuppression in patients with chronic renal failure. The activity of IL-18 can be regulated by the IL-18-binding protein (IL-18BP), a glycoprotein of 40,000 daltons, which is constitutively expressed and appears to be the natural inhibitor of IL-18 activity. Unlike soluble receptors for IL-18, IL-18BP does not have a transmembrane domain; IL-18BP is a secreted protein possessing a high-affinity binding and ability to neutralize IL-18. IL-18BP was discovered in human urine and is excreted in health following glomerular filtration. With decreasing renal function, the concentrations of IL-18BP in the circulation are elevated as compared with subjects with a normal renal function, and these elevated levels may result in a decreased IL-18 activity. Because of the importance of IL-18 and IFN-gamma in the Th1 response, the biology of IL-18 and IL-18BP is reviewed here in the context of the immunosuppression of chronic renal failure.
Dinarello CA,  et al. Blood Purif. 2003;21(3):258-70.
Soluble IL-8R1 (Human) ELISA
Code No.: SK00729-09
Size: 96 T
Price: $360.00 USD
Standard Range:7.8-500 pg/ml
Sensitivity:3 g/ml
Sample Type: serum, EDTA plasma
Dilution Factor: 40
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
Human Il-18BP ELISA
Code No.: SK00729-06
Size: 96 T
Price: $360.00 USD
Standard Range:23-1500 pg/ml
Sensitivity:10 g/ml
Sample Type: serum, EDTA plasma
Dilution Factor: 40
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
  Mouse Il-18 ELISA
Code No.: SK00729-03
Size: 96 T
Price: $360.00 USD
Standard Range:15.6-1000 pg/ml
Sensitivity:7 g/ml
Sample Type: serum, EDTA plasma
Dilution Factor: 40
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
Human IL-18 Recombinant
Code No.: 00729-01-100
Size: 100 ug
Price: $360.00 USD
Protein ID:Q14116
Gene ID: NM_001562
MW: 19 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 95%
Data Sheet: PDF
anti IL-18 monoclonal
Anti Human IL-18 Monoclonal Antibody
Code No.: A00729-02-100
Size: 100 ug
Price: $260.00 USD
Clone: 1E1H5A3
Host: mice
Purification: Protein G
Target Protein ID:Q14116
Target Gene ID: NM_001562
Positive Band MW: 22 KD (reduced)
Tag: His Tag on N-Terminus
Validation: WB and ELISA
Application: WB, E
Data Sheet: PDF
anti human IL-18 antibody from aviscera bioscience Anti IL-18 (Human) IgG
Code No.: A00729--01-100
Size: 100 ug
Price: $260.00 USD
Target Protein ID:Q14116
Target Gene ID: NM_001562
Host: Rabbit
Immunogen: Human IL-18 Rec.
Antibody Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC (2-4 ug/ml)
Data Sheet: PDF
 

 

Name
Code No.
Size
Price ($)
Human IL-18 ELISA Kit
SK00729-01
96 T
360.00
Mouse IL-18 ELISA Kit
SK00729-03
96 T
360.00
Human IL-18BP ELISA Kit
96 T
360.00
Soluble IL-18R1 (Human) ELISA Kit
SK00729-09
96 T
360.00
       
IL-18 (Human) recombinant 00729-01-100 100 ug 360.00
IL-18 (Human) Recombinant 00729-01-50 50 ug 200.00
Anti IL-18 (Human) IgG A00729-01-100 100 ug 260.00
Anti IL-18 (Human) Monoclonal Antibody A00729-02-100 100 ug 260.00